Vimgreen Pharmaceuticals progresses with Phase 2 trial of VG081821AC for Parkinson’s disease
Vimgreen Pharmaceuticals has marked a significant milestone with the completion of participant enrollment in its Phase 2 clinical trial for VG081821AC, a cutting-edge treatment for ... Read More
PhotoPharmics reaches key milestone in Light for PD trial for Parkinson’s disease
PhotoPharmics, a leader in neurodegenerative disease phototherapy, has reached a significant milestone in its Light for PD clinical trial. The company has enrolled its first ... Read More
Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA ... Read More
Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease
Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More
Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying ... Read More
Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More
SPARC achieves enrollment goal in PROSEEK Phase 2 Parkinson’s trial
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK study, a significant global Phase 2 clinical ... Read More
ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301
ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 ... Read More
Lilly wraps up acquisition of gene therapy company Prevail Therapeutics
Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US ... Read More